The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:58 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #39. Grifols Transfusion diagnostics unit of Novartis

Acquirer: Grifols (GRFS)
Acquiree: Transfusion diagnostics unit of Novartis (NVS)
Details: Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company and leading producer of plasma therapies, and Novartis (VX: NOVN, NYSE: NVS), today announced that they have signed a definitive agreement whereby Grifols will acquire the transfusion diagnostics unit of Novartis for a total amount of US$1,675 million (1,240 million).

Grifols is engaged in developing, manufacturing and distributing a range of biological medicines on plasma derived proteins. Co. organizes its business into five divisions: Bioscience, which includes activities relating to the manufacture of plasma derivatives for therapeutic use; Diagnostic, which focuses on researching, developing, manufacturing and marketing in vitro diagnostics products; Hospital, which manufactures products used by hospitals, as well as parenteral solutions and enteral nutritional fluids; Bio Supplies, which is primarily involved in biological products for non-therapeutic use; and Others, which is primarily involved in manufacturing services to third party companies.

Open the GRFS Page at The Online Investor »

Grifols is engaged in developing, manufacturing and distributing a range of biological medicines on plasma derived proteins. Co. organizes its business into five divisions: Bioscience, which includes activities relating to the manufacture of plasma derivatives for therapeutic use; Diagnostic, which focuses on researching, developing, manufacturing and marketing in vitro diagnostics products; Hospital, which manufactures products used by hospitals, as well as parenteral solutions and enteral nutritional fluids; Bio Supplies, which is primarily involved in biological products for non-therapeutic use; and Others, which is primarily involved in manufacturing services to third party companies.

Open the NVS Page at The Online Investor »

Company Name: 
Grifols SA, Barcelona
Website: 
www.grifols.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding GRFS: 
5
Total Market Value Held by ETFs: 
$87.46M
Company Name: 
Novartis AG Basel
Website: 
www.novartis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding NVS: 
4
Total Market Value Held by ETFs: 
$82.54M
Total Market Capitalization: 
$245.63B
% of Market Cap. Held by ETFs: 
0.03%
 

Quotes delayed 20 minutes


Biotechnology M&A - Slide 39 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.